Klaus Bühler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Klaus Bühler has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Monica Lispi
Merck Healthcare KGaA, 64293 Darmstadt, Germany
2 shared publications - Alberto Revelli
Gynecology and Obstetrics 2U, “AOU Città della Salute e della Scienza di Torino”, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy
1 shared publication - Arthur Allignol
Merck Healthcare KGaA, Darmstadt, Germany
1 shared publication - Claudia Roeder
Pharma Value Consulting, Oberwil, Switzerland
1 shared publication Edel Falla
IQVIA Real World Solutions, London, UK
1 shared publication- Evelyn Verbeke
Department of Public Health and Primary Care Leuven Institute for Healthcare Policy, KU Leuven Leuven Belgium
1 shared publication
Latest Publications
- Open Access
- 16 February 2022
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 85 (Pt B) , 188-202
Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry
- 16 February 2022
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 85 (Pt B) , 188-202
Open AccessCost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry
- Open Access
- 2 February 2022
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 85 (Pt B) , 217-228
Economic evaluation of Medically Assisted Reproduction: An educational overview of methods and applications for healthcare professionals
- 2 February 2022
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 85 (Pt B) , 217-228
Open AccessEconomic evaluation of Medically Assisted Reproduction: An educational overview of methods and applications for healthcare professionals
- Open Access
- 1 January 2014
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 12 (1) , 6
A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology
Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) both have a role to play in follicular development during the natural menstrual cycle. LH supplementation during controlled ovarian stimulation (COS) for assisted reproductive technology (ART) is used for patients with hypogonadotropic hypogonadism. However, the use of exogenous LH in COS in normogonadotropic women undergoing ART is the subject of debate. The aim of this study was to investigate characteristics of infertile women who received the 2:1 formulation of follitropin alfa and lutropin alfa (indicated for stimulation of follicular development in women with severe LH and FSH deficiency) in German clinical practice.
- 1 January 2014
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 12 (1) , 6
Open AccessA large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology
Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) both have a role to play in follicular development during the natural menstrual cycle. LH supplementation during controlled ovarian stimulation (COS) for assisted reproductive technology (ART) is used for patients with hypogonadotropic hypogonadism. However, the use of exogenous LH in COS in normogonadotropic women undergoing ART is the subject of debate. The aim of this study was to investigate characteristics of infertile women who received the 2:1 formulation of follitropin alfa and lutropin alfa (indicated for stimulation of follicular development in women with severe LH and FSH deficiency) in German clinical practice.